646-19-5NCCCCCCCNPWSKHLMYTZNYKO-UHFFFAOYSA-N646-19-5DTXSID60214848CHEMBL28242Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Danger
H314 (100%): Causes severe skin burns and eye damage [Danger Skin corrosion/irritation]
P260, P264, P280, P301+P330+P331, P302+P361+P354, P304+P340, P305+P354+P338, P316, P321, P363, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 47 reports by companies from 5 notifications to the ECHA C&L Inventory.
Uses1,7-Diaminoheptane is used in the preparation of 7-amino-1-guanidinooctane and 1,7-diamino-trans-hept-3-ene, which is used as a deoxyhypusine synthase inhibitor.
PreparationStep 1 involves the hydroxylation of cycloheptane to cycloheptanol, catalyzed by enzyme p450 in the presence of the endogenous cofactor NADPH. Step 2 involves the oxidation of cycloheptanol to cycloheptanone, catalyzed by alcohol dehydrogenase (ADH) in the presence of NADP+, followed by the conversion of cycloheptanone to heptanolide by Baeyer-Villiger oxidase (BVMO). Heptanolide is then hydrolyzed by lactonease (Lac) to 7-hydroxyheptanoic acid, which is subsequently reduced to 1,7-heptanediol by CAR (with the aid of phosphoethyl ester transferase (SFP)) and endogenous aldehyde-ketone reductase (AKR). Step 3 involves two rounds of oxidation/amination reactions catalyzed by ChnD and TA: first, 1,7-heptanediol is oxidized to 7-hydroxyheptanal by ChnD, then amination with TA to 7-aminoheptanol, then oxidized again by ChnD to 7-aminoheptanal, and finally amination with TA to 1,7-diaminoheptane.